NCT05414981 - A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-H3733 in Subjects With Chronic Hepatitis B Virus Infection | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 7, 2022

Primary Completion Date

April 24, 2023

Study Completion Date

April 24, 2023

Conditions

Chronic Hepatitis B

Interventions

DRUG

ABI-H3733

25 mg or 100 mg tablets for oral administration

DRUG

Placebo

25 mg or 100 mg tablets for oral administration

Trial Locations (9)

1051

New Zealand Clinical Research, Grafton

1407

Acibadem City Clinic Tokuda Hospital, Sofia

1431

Diagnostic Consultative Center Aleksandrovska, Sofia

1606

Military Medical Academy Multiprofile Hospital for Active Treatment - Sofia, Sofia

168753

Clinical Trials and Research Centre, Singapore General Hospital, Singapore

Unknown

University of Hong Kong, Hong Kong

National University Hospital, Singapore

MD-2025

"ICS Arensia Exploratory Medicine Republican Clinical Hospital Timofei Moșneaga- Hospital", Chisinau

021105

"Institute of Infectious Diseases - Hospital ARENSIA Exploratory Medicine Research Clinic National Institute of Infectious Diseases Matei Bals", Bucharest